[go: up one dir, main page]

MX2019000588A - Moduladores de la somatostatina y usos de los mismos. - Google Patents

Moduladores de la somatostatina y usos de los mismos.

Info

Publication number
MX2019000588A
MX2019000588A MX2019000588A MX2019000588A MX2019000588A MX 2019000588 A MX2019000588 A MX 2019000588A MX 2019000588 A MX2019000588 A MX 2019000588A MX 2019000588 A MX2019000588 A MX 2019000588A MX 2019000588 A MX2019000588 A MX 2019000588A
Authority
MX
Mexico
Prior art keywords
compounds
somatostatin
modulators
methods
somatostatin modulators
Prior art date
Application number
MX2019000588A
Other languages
English (en)
Other versions
MX390120B (es
Inventor
Wang Shimiao
Zhao Jian
Han Sangdon
Hee Kim Sun
Zhu Yunfei
Original Assignee
Crinetics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinetics Pharmaceuticals Inc filed Critical Crinetics Pharmaceuticals Inc
Publication of MX2019000588A publication Critical patent/MX2019000588A/es
Publication of MX390120B publication Critical patent/MX390120B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

En el documento se describen compuestos que son moduladores de la somatostatina, métodos para la elaboración de dichos compuestos, composiciones farmacéuticas y medicamentos que comprenden dichos compuestos, así como métodos para la utilización de dichos compuestos en el tratamiento de las afecciones, enfermedades, o trastornos que podrían beneficiarse de la modulación de la actividad de la somatostatina.
MX2019000588A 2016-07-14 2017-07-12 Moduladores de la somatostatina y usos de los mismos. MX390120B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662362493P 2016-07-14 2016-07-14
US201662411338P 2016-10-21 2016-10-21
PCT/US2017/041694 WO2018013676A1 (en) 2016-07-14 2017-07-12 Somatostatin modulators and uses thereof

Publications (2)

Publication Number Publication Date
MX2019000588A true MX2019000588A (es) 2019-09-09
MX390120B MX390120B (es) 2025-03-20

Family

ID=60941935

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000588A MX390120B (es) 2016-07-14 2017-07-12 Moduladores de la somatostatina y usos de los mismos.

Country Status (24)

Country Link
US (7) US9896432B2 (es)
EP (2) EP4163276A1 (es)
JP (2) JP6967577B2 (es)
KR (2) KR102324042B1 (es)
CN (2) CN115557929A (es)
AU (2) AU2017296392B2 (es)
CA (1) CA3030423A1 (es)
DK (1) DK3484865T3 (es)
ES (1) ES2931472T3 (es)
HR (1) HRP20221279T1 (es)
HU (1) HUE060182T2 (es)
IL (1) IL264178B2 (es)
LT (1) LT3484865T (es)
MX (1) MX390120B (es)
NZ (1) NZ750174A (es)
PL (1) PL3484865T3 (es)
PT (1) PT3484865T (es)
RS (1) RS63776B1 (es)
SG (1) SG11201900349VA (es)
SM (1) SMT202200465T1 (es)
TW (1) TWI789355B (es)
UA (1) UA125393C2 (es)
WO (1) WO2018013676A1 (es)
ZA (1) ZA201900317B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2931472T3 (es) 2016-07-14 2022-12-29 Crinetics Pharmaceuticals Inc Moduladores de somatostatina y usos de los mismos
EA201992083A1 (ru) * 2017-03-16 2020-03-18 Кринетикс Фармасьютикалс, Инк. Модуляторы соматостатина и их применения
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
ES2923529T3 (es) * 2018-01-17 2022-09-28 Crinetics Pharmaceuticals Inc Proceso para fabricar moduladores de somatostatina
EP3752498B1 (en) 2018-02-12 2023-06-28 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3807248A4 (en) * 2018-05-29 2021-10-27 Council of Scientific and Industrial Research BICYCLIC TOPOISOMERASE I INHIBITOR COMPOUNDS, THEIR PREPARATION AND USE
DK3853218T3 (da) 2018-09-18 2025-04-22 Crinetics Pharmaceuticals Inc Somatostatinmodulatorer og anvendelser deraf
EP3999509A4 (en) 2019-07-17 2023-07-19 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
TWI841768B (zh) * 2019-08-14 2024-05-11 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
AU2021341936A1 (en) * 2020-09-09 2023-05-25 Crinetics Pharmaceuticals, Inc. Formulations of a somatostatin modulator
CN117043149A (zh) 2021-02-17 2023-11-10 克林提克斯医药股份有限公司 促生长素抑制素调节剂的结晶形式
BR112023024465A2 (pt) * 2021-05-25 2024-02-06 Crinetics Pharmaceuticals Inc Usos de um modulador de somatostatina para o tratamento de doença
US20240352175A1 (en) 2021-09-28 2024-10-24 Denka Company Limited Chloroprene block copolymer, latex, latex composition, and rubber composition
JP2025501922A (ja) * 2022-01-11 2025-01-24 クリネティックス ファーマシューティカルズ，インク． カルチノイド症候群の治療のためのソマトスタチンモジュレータの使用
US20250361221A1 (en) 2022-06-10 2025-11-27 Assia Chemical Industries Ltd. Solid state forms of paltusotine and process for preparation thereof
KR20250113414A (ko) * 2022-10-28 2025-07-25 베이스캠프 바이오 인코포레이티드 소마토스타틴 수용체 2 작용제 및 이의 용도
WO2024129614A1 (en) 2022-12-13 2024-06-20 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof
AU2024242719A1 (en) 2023-03-28 2025-09-25 Crinetics Pharmaceuticals, Inc. Compositions and methods for administering paltusotine to patients with hepatic impairment
TW202523316A (zh) * 2023-11-22 2025-06-16 美商克林提克斯醫藥股份有限公司 生長抑制素亞型3受器（sstr3）激動劑及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1035154A (en) 1910-05-16 1912-08-13 Ernest G Clark Machine for rectifying perforated music and masters.
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
US20050009815A1 (en) 2001-11-27 2005-01-13 Devita Robert J. 4-Aminoquinoline compounds
JP4216196B2 (ja) * 2002-02-04 2009-01-28 エフ．ホフマン−ラ ロシュ アーゲー Ｎｐｙアンタゴニストとしてのキノリン誘導体
US7767817B2 (en) 2003-09-05 2010-08-03 Binghe Wang Water soluble boronic acid fluorescent reporter compounds and methods of use thereof
JP2008506695A (ja) * 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
US20060183763A1 (en) 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
NZ569485A (en) 2005-12-05 2011-06-30 Xenoport Inc Levodopa prodrug mesylate, compositions thereof, and uses thereof
WO2007098214A1 (en) 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
EP1996574A1 (en) 2006-03-08 2008-12-03 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
AU2007309708A1 (en) 2006-03-13 2008-05-02 Merck Sharp & Dohme Corp. Somatostatin agonists
BRPI0918496A2 (pt) 2008-09-02 2019-09-24 Novartis Ag composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula
GB0818241D0 (en) * 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
SG10201505951VA (en) * 2010-07-30 2015-08-28 Oncotherapy Science Inc Quinoline derivatives and melk inhibitors containing the same
EP2726465A1 (en) 2011-05-23 2014-05-07 Elan Pharmaceuticals Inc. Inhibitors of lrrk2 kinase activity
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
DE102011113749A1 (de) 2011-09-14 2013-03-14 Aicuris Gmbh & Co. Kg Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
US20140228417A1 (en) 2011-10-05 2014-08-14 Mapi Pharma Ltd. Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
CA2888485C (en) * 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror.gamma.t
JP6380402B2 (ja) 2013-09-30 2018-08-29 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
EP3124487A1 (en) 2014-03-24 2017-02-01 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3317278B1 (en) 2015-07-01 2021-04-14 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
UA124802C2 (uk) 2015-12-17 2021-11-24 Мерк Патент Гмбх Поліциклічні антагоністи tlr7/8 і їх застосування в лікуванні імунних розладів
WO2018009735A1 (en) 2016-07-07 2018-01-11 Plantex Ltd. Solid state forms of palbociclib dimesylate
ES2931472T3 (es) 2016-07-14 2022-12-29 Crinetics Pharmaceuticals Inc Moduladores de somatostatina y usos de los mismos
ES2923529T3 (es) 2018-01-17 2022-09-28 Crinetics Pharmaceuticals Inc Proceso para fabricar moduladores de somatostatina
DK3853218T3 (da) 2018-09-18 2025-04-22 Crinetics Pharmaceuticals Inc Somatostatinmodulatorer og anvendelser deraf
EP3999509A4 (en) 2019-07-17 2023-07-19 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
AU2021341936A1 (en) 2020-09-09 2023-05-25 Crinetics Pharmaceuticals, Inc. Formulations of a somatostatin modulator

Also Published As

Publication number Publication date
AU2017296392A1 (en) 2019-02-28
KR102324042B1 (ko) 2021-11-09
CN109715612A (zh) 2019-05-03
IL264178B2 (en) 2024-05-01
US10875839B2 (en) 2020-12-29
JP2022028675A (ja) 2022-02-16
PT3484865T (pt) 2022-11-03
BR112019000692A2 (pt) 2019-04-24
US10597377B2 (en) 2020-03-24
IL264178B1 (en) 2024-01-01
EP3484865A4 (en) 2019-12-25
US20260008767A1 (en) 2026-01-08
UA125393C2 (uk) 2022-03-02
EP3484865B1 (en) 2022-09-14
ZA201900317B (en) 2022-10-26
IL264178A (en) 2019-02-28
SMT202200465T1 (it) 2023-01-13
US20190002431A1 (en) 2019-01-03
US9896432B2 (en) 2018-02-20
RS63776B1 (sr) 2022-12-30
PL3484865T3 (pl) 2023-01-09
EP4163276A1 (en) 2023-04-12
SG11201900349VA (en) 2019-02-27
TW201805276A (zh) 2018-02-16
US20200190053A1 (en) 2020-06-18
CN115557929A (zh) 2023-01-03
DK3484865T3 (da) 2022-10-31
LT3484865T (lt) 2022-11-10
US20190382367A1 (en) 2019-12-19
HUE060182T2 (hu) 2023-02-28
HRP20221279T1 (hr) 2022-12-23
ES2931472T3 (es) 2022-12-29
NZ750174A (en) 2023-04-28
US20220380337A1 (en) 2022-12-01
KR20190026914A (ko) 2019-03-13
US11414397B2 (en) 2022-08-16
US20210171492A1 (en) 2021-06-10
EP3484865A1 (en) 2019-05-22
AU2020277122A1 (en) 2020-12-24
TWI789355B (zh) 2023-01-11
CN109715612B (zh) 2022-09-16
JP6967577B2 (ja) 2021-11-17
JP2019520415A (ja) 2019-07-18
US20180016252A1 (en) 2018-01-18
CA3030423A1 (en) 2018-01-18
US10351547B2 (en) 2019-07-16
MX390120B (es) 2025-03-20
KR20210134838A (ko) 2021-11-10
BR112019000692A8 (pt) 2022-03-03
WO2018013676A1 (en) 2018-01-18
AU2017296392B2 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
CL2019000979A1 (es) Composiciones y anticuerpos anti-lag-3.
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
MX2017011269A (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2016001895A1 (es) Compuestos
MX2017014375A (es) Moduladores del ccr2.
MX2015011448A (es) Compuestos y sus usos para modular la hemoglobina.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2015011769A (es) Compuestos y sus usos para modular la hemoglobina.
MX2019010949A (es) Moduladores de somatostatina y usos de los mismos.
EA201692109A1 (ru) Варианты антител к фактору d и их применение
HK1255034A1 (zh) 生长抑素调节剂及其用途
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
HK1255074A1 (zh) 生长抑素调节剂及其用途
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.